samedan logo
 
 
 
spacer
home > pmps > autumn 2008 > the dry deal
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Dry Deal

It is clear that the respiratory route is highly effective for the delivery of an increasingly wide variety of therapeutic drugs, both locally acting and systemic. A number of different delivery platforms exist, and one currently receiving much attention is the dry powder inhaler (DPI). Requiring no propellant, these devices are simple to use, have a wide dose range and offer advantages over other systems when delivering a range of molecules, small or large.

Successful drug delivery with DPIs relies on closely matching the formulation and delivery device, and optimising the two in tandem. The efficacy of delivery will be affected by the particle size and velocity of the inhaled aerosol cloud which determine, for example, whether the drug is deposited into the lungs or in the throat. Consequently, a large part of the design process involves detailed analysis of the inhaled cloud, including measuring the size of the constituent particles. Laser diffraction-based particle size analysis is used extensively in this work, providing insight that promotes a ‘quality by design’ (QbD) approach and more efficient product development.

This article will examine how the technique improves understanding of both formulation and device behaviour. It is also relevant to include some discussion of the factors affecting powder dispersion, as well as present experimental work that illustrates how different excipients can enhance the performance of a formulation.

ADVANTAGES OF DPIS

DPIs offer a number of advantages over other inhalation devices. For example, since the delivery process is actuated by inspiration, the user is not required to coordinate different actions. DPIs do not suffer from the...

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr David Morton gained a PhD from Bristol University in the UK in Structural Chemistry. He then spent 8 years in the UK nuclear industry with AEA Technology, developing expertise in the generation and transport of aerosols. In 1997, he joined the Centre for Drug Formulation Studies, University of Bath, managing their dry powder inhaler product development programmes. In 1999, this group spun out into the drug delivery company Vectura, where David was Head of Pulmonary Research, and latterly Head of Intellectual Property and Technology. He is currently Senior Lecturer in Formulation Science at the Victorian College of Pharmacy, Monash University, Australia. David has had a major role in developing the annual ‘Drug Delivery to the Lung’ international series of conferences on behalf of the Aerosol Society since 1997.

Dr Paul Kippax has a degree in Chemistry and a PhD in Colloid and Interface Science, both obtained at the University of Nottingham, UK. He joined Malvern Instruments in 1997 as an applications scientist and in 2002 became product manager for the company’s laser diffraction particle size analysis systems. He has worked closely with the pharmaceutical industry in understanding how laser diffraction techniques can be best applied to characterising the performance of medical devices. This has included the publication of several joint research articles relating to the optimisation of drug delivery from dry powder inhalers and nasal sprays.

spacer
Dr David Morton
spacer
spacer
spacer
Dr Paul Kippax
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Arcis Biotechnology appointments Professor Steve Howell as Non-Executive Chairman

Daresbury, UK, 24 July 2019: Arcis Biotechnology (“Arcis”), the nucleic acid sample preparation solution provider, today announced it has appointed Professor Steve Howell as Non-Executive Chairman of its Board of Directors. Steve takes over the position from Paul Foulger, who was serving as Chairman on an interim basis on behalf of the Board.
More info >>

White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement